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Summary
Background Previous studies have found rotavirus vaccination to be highly cost-effective in low-income countries. 
However, updated evidence is now available for several inputs (ie, rotavirus disease mortality rates, rotavirus age 
distributions, vaccine timeliness, and vaccine efficacy by duration of follow-up), new rotavirus vaccines have entered 
the market, vaccine prices have decreased, and cost-effectiveness thresholds have been re-examined. We aimed to 
provide updated cost-effectiveness estimates to inform national decisions about the new introduction and current use 
of rotavirus vaccines in Gavi countries.
Methods We calculated the potential costs and effects of rotavirus vaccination for ten successive birth cohorts in 
73 countries previously and currently eligible for Gavi support, compared with no vaccination. We used a deterministic 
cohort model to calculate numbers of rotavirus gastroenteritis cases, outpatient visits, hospitalisations, and deaths 
between birth and 5 years, with and without rotavirus vaccination. We calculated treatment costs from the government 
and societal perspectives. The primary outcome measure was the incremental cost-effectiveness ratio (discounted US$ 
per disability-adjusted life-year averted). Country-specific model input parameters were based on the scientific literature, 
published meta-analyses, and international databases. We ran deterministic and probabilistic uncertainty analyses.
Findings Over the period 2018–27, rotavirus vaccination has the potential to prevent nearly 600 000 deaths in 
Gavi countries. Averted outpatient visits and hospitalisations could lead to treatment savings of approximately 
$484·1 million from the government perspective and $878·0 million from the societal perspective. The discounted 
dollars per disability-adjusted life-year averted has a very high probability (>90%) of being less than 0·5 times the gross 
domestic product per capita in 54 countries, and less than 1·0 times gross domestic product per capita in 63 countries.
Interpretation Rotavirus vaccination continues to represent good value for money across most Gavi countries despite 
lower rotavirus mortality estimates and more stringent willingness-to-pay thresholds.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Diarrhoeal diseases are estimated to cause over half 
a million deaths each year in children younger than 
5 years.1–3 This proportion is roughly 10% of all deaths in 
this age group, with most deaths occurring in the world’s 
poorest countries. A large proportion (24–37%) of these 
deaths are estimated to be caused by rotavirus.4,5
The introduction of rotavirus vaccines has played an 
important role in contributing to declines in diarrhoeal 
mortality and morbidity.6 In 2009, WHO recommen­
ded introduction of rotavirus vaccination in all national 
immunisation programmes.7 Over 90 countries have intro­
duced the vaccine, with low­income countries bene fiting 
from the financial support of Gavi, the Vaccine Alliance.8,9 
These introductions have had a profound effect on public 
health, not just from a rotavirus mortality and morbidity 
perspective, but also by freeing health­care resources for 
other priorities in resource­constrained settings.6
In addition to the declining diarrhoea burden, the 
incomes of the world’s poorest regions are also growing. 
For example, between 2005 and 2015, real income per 
capita increased by nearly 25% in sub­Saharan Africa.10 
Growing incomes have the potential to increase living 
standards, reduce poverty, and enable governments to 
raise additional revenue. Conversely, as incomes grow, 
countries have less access to international financing 
mechanisms to support health and development object­
ives. International donors, such as Gavi, the Global 
Fund, and the World Bank International Development 
Association all offer financial support to countries, but 
this support is linked to country income.11–13 As a result, 
countries could face the same challenges with fewer 
resources to meet them. Furthermore, many of the 
countries that have yet to introduce rotavirus vaccination 
are no longer eligible for Gavi funding.9,14 In all countries 
that have received financial support from Gavi, the 
government is expected to eventually incur the full costs 
of the programme when Gavi’s support expires.
In 2012, Atherly and colleagues15 published an impact 
and cost­effectiveness analysis of rotavirus vaccination in 
countries eligible for Gavi’s support. This, and many other 
studies, found rotavirus vaccination to be highly cost­
effective in low­income and middle­income countries 
around the world.16–20 However, the guidance around 
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cost­effectiveness thresholds used to interpret inter­
ventions has changed, calling for the use of more stringent 
thresholds that better reflect the financial constraints of 
these countries.21 In addition, estimates of rotavirus pre­
vaccination mortality have decreased from 453 000 in 
2008 to 215 000 in 2013.4,22 Updated evidence is available 
for rotavirus age distributions, vaccine timeliness, vaccine 
efficacy, and rotavirus disease treatment costs. The price 
of rotavirus vaccines has also been decreasing as new 
products have entered the global market. All these factors 
are important variables in a cost­effectiveness study. The 
purpose of this Article is to assess the potential impact 
and cost­effectiveness of rotavirus vaccination across 
73 countries (currently and previously eligible for Gavi 
support) as a result of these important global trends.
Methods
Study design
We examined the projected impact and cost­effectiveness 
of rotavirus vaccination in 73 countries previously or 
currently eligible for Gavi support, across all WHO 
regions (table 1). Results were generated and reported 
per country and then aggregated per WHO regions and 
for all Gavi countries. We calculated the potential costs 
and benefits of nationwide infant rota virus vaccination, 
compared with no vaccination, for ten consecutive birth 
cohorts (2018–27) in 73 Gavi countries.
Rotavirus gastroenteritis cases, outpatient visits, hos­
pitalisations (hospital admission), deaths, and costs were 
projected over the first 5 years of life. During the period of 
analysis, the vaccinated individuals could or could not 
become ill with rotavirus disease. If they got rotavirus 
disease, it could be non­severe or severe. Non­severe 
disease was defined as recovery with or without outpatient 
care (clinic visit). Severe disease was defined as recovery 
or death with or without outpatient or inpatient care. We 
did not consider informal care in this analysis.
Costs and benefits were examined from both the 
government and societal perspectives and are discounted 
at 3% per year. Monetary units were presented in 
2015 US$. Key outputs of the analysis included aversions 
of deaths, disability­adjusted life­years (DALYs), cases, 
hospitalisations and outpatient visits, and health costs as 
a result of rotavirus vaccination. Additional outputs 
included the total costs of vaccination and our primary 
outcome measure, the incremental cost­effectiveness 
ratio (ICER), expressed as discounted US$ per DALY 
averted. To allow for comparison of ICERs with a uni­
form willingness­to­pay threshold that we applied to all 
countries, gross domestic product (GDP) and population 
values for each country were used to calculate values 
for individual countries, regions (WHO regions), and all 
Gavi countries’ GDP per capita. We then used model­
generated ICERs and compared the ICER with cost­
effectiveness thresholds of 0·5 times and 1·0 times GDP 
per capita in all examined countries.
Impact and cost-effectiveness model
We used a Microsoft Excel­based static cohort model with 
a finely disaggregated age structure (weeks of age up to 
5 years) to calculate numbers of rotavirus gastroenteritis 
cases, clinic visits, hospitalisations, and deaths expected 
to occur between birth and age 5 years, with and without 
rotavirus vaccination (UNIVAC version 1.3.41).23 Methods 
Research in context
Evidence before this study
Rotavirus is a leading cause of childhood deaths caused by 
diarrhoea worldwide. Rotavirus vaccines have been available for 
the past 10 years and introduced in many countries, including 
countries receiving support from Gavi, the Vaccine Alliance. 
In countries where they are used, rotavirus vaccines have 
contributed to the decrease of rotavirus gastroenteritis cases and 
deaths. We searched PubMed, Google Scholar, and Web of 
Science from Jan, 2008 to April, 2019 using broad search terms 
associated with “rotavirus”, “vaccine”, “cost-effective”, “Gavi”, 
and “low- and middle-income country”. We supplemented 
identified articles with studies known to the authors. The 
cost-effectiveness of rotavirus vaccination has been shown in 
Gavi-eligible countries in several analyses and many analyses in 
specific low-income and middle-income countries. However, 
global trends have potentially affected the cost-effectiveness 
profile of rotavirus vaccines: economic growth has led to a 
decrease in international support as recipient countries grow 
wealthier; updated evidence is showing lower rotavirus 
mortality; the guidance around cost-effectiveness thresholds 
used to interpret interventions has changed, calling for the use of 
more stringent thresholds; new products have entered the 
market; and evidence for several model inputs has been updated.
Added value of this study
Our study provides an update on the cost-effectiveness of 
rotavirus vaccination in previous and current Gavi-eligible 
countries. We covered more vaccines than in previous studies, 
including two new, potentially more affordable rotavirus 
vaccines that entered the market in 2018. The study generates 
numbers of rotavirus cases, clinic visits, hospitalisations, deaths, 
and treatment costs averted by vaccination, by country and 
region. We also calculated costs for vaccination programmes for 
vaccines with different characteristics.
Implications of all the available evidence
Our study provides evidence that rotavirus vaccination is still a 
cost-effective investment in Gavi countries. Additional rotavirus 
burden could be averted with more countries adopting the 
vaccines. Policy makers in countries with reducing international 
support and who are looking for budget efficiencies should 
consider newly available products as they might offer more 
affordable options.
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used to calculate the direct effects of vaccination have 
been described in detail elsewhere.24,25 In brief, for each 
week of age, the expected number of disease events (ie 
cases, visits, hospitalisations, deaths) were multiplied by 
the expected coverage (adjusted for vaccine timeliness) 
and efficacy (adjusted for duration of follow­up) of each 
dose of vaccination. Health­care costs were calculated 
by multiplying the expected numbers of clinic visits 
and hospitalisations by the average cost per clinic visit 
and hospitalisation, from a government and societal 
perspective. Vaccination costs were calculated by multi­
plying the total number of doses administered by a 
wastage factor and other assumptions about price and the 
costs of delivery. More details on input parameters and 
values for each country are included later in this Article.
Disease burden
We estimated approximately 10 000 symptomatic rota­
virus gastroenteritis cases per 100 000 children aged 
younger than 5 years per year on the basis of a global 
systematic review and meta­analysis by Bilcke and 
colleagues.26 We used WHO region estimates of the pro­
portion of all­cause gastroenteritis cases that are severe 
(defined as children with moderate or severe dehydra­
tion), as a proxy for the proportion of rotavirus 
gastroenteritis cases that were severe (and non­severe).27 
To calculate numbers of rotavirus deaths in each country 
(without vaccination), we estimated means (and 95% CIs) 
using country­specific estimates from three difference 
sources (Institute for Health Metrics and Evaluation, 
Maternal Child Epidemiology Estimation, and WHO US 
Centers for Diseases Control and Prevention) for the year 
2015.1,3,4 We elected to use the mean because the range 
reported by the three different sources was from 
158 000 to 202 000 deaths a year in children younger than 
5 years for the group of 73 countries. Comparison and 
discussion of methods and results from the three sources 
have been published elsewhere.5 If a country had already 
introduced the vaccine in 2015, then the mortality for the 
most recent prevaccination year was used, using 
WHO–UNICEF joint estimates of national immunisation 
coverage to determine the most recent prevaccine year.28 
In absence of vaccination, we assumed that rotavirus 
mortality would decrease at the same rate as all­cause 
mortality for children younger than 5 years of age. 
Rotavirus age distributions were based on a systematic 
review and statistical analysis of over 90 hospital 
datasets.29 We assumed that 20% of severe rotavirus 
gastroenteritis cases would require a hospital admission 
and further reduced this proportion to account for those 
without access to hospital, using coverage of the first 
dose of diphtheria–tetanus–pertussis vaccine (DTP1) as a 
proxy for access to care. This method generated rates of 
rotavirus gastro enteritis hospitalisations that were 
consistent with pre vaccination rates previously reported 
(around 350 per 100 000 per year, among children 
younger than 5 years).30–36 We assumed that 100% of 
severe rotavirus gastroenteritis cases and 10% of non­
severe cases would require a clinic visit, and again used 
DTP1 coverage to adjust for access to care. DALY weights 
were taken from the 2013 Global Burden of Disease 
study,37 using values reported for mod erate diarrhoea 
as a proxy of non­severe rotavirus gastro enteritis and 
for severe diarrhoea as a proxy of severe rotavirus 
gastroenteritis. We assumed a duration of illness of 
4 days for non­severe rotavirus gastroenteritis and 6 days 
for severe rotavirus gastroenteritis cases and explored 
longer and shorter durations in probabilistic analysis.38 
Input values and ranges for DALY weights and duration 
of illness are available in the appendix.
Vaccine preference, coverage, and efficacy
Four rotavirus vaccines prequalified by WHO at end of 
2018 were considered in the analysis. These four vaccines 
were Rotarix (manufactured by GlaxoSmithKline, 
Rixensart, Belgium), RotaTeq (manufactured by Merck 
African region Region of the 
Americas
Eastern 
Mediterranean 
region
European region South-East Asia 
region
Western Pacific region
Initial 
self-financing
Benin; Burkina Faso; Burundi; Central African Republic; Chad; 
Comoros; DR Congo; Eritrea; Ethiopia; Guinea; Guinea-Bissau; 
Liberia; Madagascar; Malawi; Mali; Mozambique; Niger; 
Rwanda; Senegal; Sierra Leone; South Sudan*; Tanzania; 
The Gambia; Togo; Uganda; Zimbabwe
Haiti Afghanistan; 
Somalia
·· Nepal; North Korea† ··
Preparatory 
transition
Cameroon; Côte d’Ivoire; Ghana; Kenya; Lesotho; 
Mauritania; Zambia
·· Djibouti; Pakistan; 
Sudan; Yemen
Kyrgyzstan†;Tajikistan Bangladesh; 
Myanmar
Cambodia
Accelerated 
transition
Nigeria; São Tomé and Príncipe Nicaragua† ·· Uzbekistan India Laos; Papua New Guinea; 
Solomon Islands; Vietnam†
Fully 
self-financing
Angola; Republic of Congo Bolivia; Cuba; 
Guyana; Honduras
·· Armenia†; Azerbaijan; 
Georgia; Moldova†; 
Ukraine
Bhutan; Indonesia; 
Sri Lanka; 
Timor-Leste
Kiribati; Mongolia†
*Country not included in Atherly et al.15 †Countries with medium under-5 mortality over the period 2010–15. Different vaccine efficacy assumptions were applied to countries with medium under-5 mortality and 
high under-5 mortality over the period 2010–15; all other countries are considered to have high mortality.
Table 1: Countries considered in the analysis by WHO region and Gavi transition phase (2018)
See Online for appendix
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and Co, Kenilworth, NJ, USA), Rotavac (manufactured 
by Bharat Biotech, Hyderabad, India), and Rotasiil 
(manufactured by Serum Institute, Pune, India).39 
Rotarix was administered in a two­dose schedule 
whereas the other vaccines were administered in a 
three­dose schedule. Our base­case scenario explored all 
73 countries with the vaccine they were using in 2018 
for countries already using rotavirus vaccines, and a 
randomly allocated vaccine (Rotavac or Rotasiil) for 
countries that were not using rotavirus vaccine at the 
time of analysis.9 This process did not imply a preference 
for any vaccine but ensured that new products were 
represented in this analysis. We assumed the use of both 
Rotavac and Rotasiil in India was a 50–50 distribution 
countrywide. We also ran so­called what­if scenarios 
in which all 73 countries used the same product.
Coverage of each dose of rotavirus vaccine is based on 
the WHO–UNICEF estimates of national immunisation 
coverage.28 The average of DTP1 and DTP3 coverage 
is used as a proxy for DTP2 coverage. Coverage 
rates are considered constant throughout the analysis. 
Data for vaccine coverage time liness were taken from 
Clark and colleagues.25 Assump tions about vaccine 
efficacy and waning were based on pooled data from 
published randomised controlled trials of rotavirus 
vaccines that are described elsewhere.40 In brief, in 
settings with medium under­5 mortality (defined as 
13·5–28·1 deaths per 1000 livebirths) pooled efficacy 
was 82% (95% credibility interval 74–92%) after 2 weeks 
of follow­up and 77% (67–84) after 12 months, based on 
11 observations. In settings with high under­5 mortality 
(defined as >28·1 deaths per 1000 livebirths) pooled 
efficacy was 66% (95% credibility interval 48–81) after 
2 weeks of follow­up and 44% (27–59) after 12 months, 
based on 24 observations. We did not apply any age 
restriction to the vaccine schedule.41
Vaccine price and delivery costs
Given the importance of Gavi’s support to countries, we 
examined costs of vaccine programmes with and 
without a Gavi subsidy for the vaccine. The costs with 
a Gavi subsidy was reflected in the government’s 
perspective as this cost is to the country only. The 
costs without a Gavi subsidy, representing the cost to 
countries and to Gavi, were reflected in the societal 
perspective. As such, the government perspective used 
each country’s cofinancing share based on the Gavi 
transition policy.11,42 The societal perspective reflected 
each vaccine price: $2·29 per dose for Rotarix ($6·50 for 
countries procuring through the Pan American Health 
Organization revolving fund), $3·20 for RotaTeq, 
$0·85 for Rotavac, and $0·95 for Rotasiil.43 The 
countries that did not introduce rotavirus vaccine 
when they were still eligible for Gavi support are not 
automatically accessing Gavi negotiated prices. For 
these countries, prices were estimated from the WHO 
vaccine, price, and procurement database (table 2).44,45
Vaccine 
preference
Vaccine price per 
dose (US$)
Average 
cofinancing per 
dose over 2018–27 
period (US$)
Introduction 
year
Afghanistan Rotarix 2·29 0·20 2018
Angola Rotarix 2·29 2·29 2014
Armenia Rotarix 2·29 2·29 2012
Bolivia Rotarix 6·50 6·50 2008
Burkina Faso RotaTeq 3·20 0·13 2013
Burundi Rotarix 2·29 0·20 2013
Cameroon Rotarix 2·29 0·90 2014
Côte d’Ivoire RotaTeq 3·20 1·56 2017
Djibouti Rotarix 2·29 0·53 2014
Eritrea Rotarix 2·29 0·23 2014
Ethiopia Rotarix 2·29 0·21 2013
Georgia Rotarix 2·29 2·29 2013
Ghana Rotarix 2·29 0·67 2012
Guinea-Bissau Rotarix 2·29 0·20 2015
Guyana Rotarix 6·50 6·50 2010
Haiti Rotarix 6·50 0·20 2013
Honduras Rotarix 6·50 6·50 2009
India* Rotavac/Rotasiil 0·85/0·95 0·85/0·95 2017
Kenya Rotarix 2·29 0·87 2014
Kiribati Rotarix 6·20 6·20 2015
Lesotho Rotarix 2·29 0·46 2017
Liberia Rotarix 2·29 0·20 2016
Madagascar Rotarix 2·29 0·20 2014
Malawi Rotarix 2·29 0·20 2012
Mali RotaTeq 3·20 0·13 2014
Mauritania Rotarix 2·29 0·55 2014
Moldova Rotarix 2·29 2·29 2012
Mozambique Rotarix 2·29 0·20 2015
Nicaragua Rotarix 6·50 5·98 2006
Niger Rotarix 2·29 0·20 2014
Pakistan Rotarix 2·29 1·25 2017
Republic of Congo Rotarix 2·29 2·29 2014
Rwanda Rotarix 2·29 0·20 2012
São Tomé and Príncipe RotaTeq 3·20 2·36 2016
Senegal Rotarix 2·29 0·20 2014
Sierra Leone Rotarix 2·29 0·20 2014
Sudan Rotarix 2·29 1·34 2011
Tajikistan Rotarix 2·29 0·60 2015
Tanzania Rotarix 2·29 0·20 2012
The Gambia Rotarix 2·29 0·20 2013
Togo Rotarix 2·29 0·20 2014
Uganda Rotarix 2·29 0·20 2018
Uzbekistan Rotarix 2·29 2·29 2014
Yemen Rotarix 2·29 0·68 2012
Zambia Rotarix 2·29 0·74 2013
Zimbabwe Rotarix 2·29 0·20 2014
These data are for countries already using rotavirus vaccines at the end of 2018; countries not using rotavirus vaccines 
at the end of 2018 were randomly allocated one of the newly prequalified vaccines. *Assuming that 50% of immunised 
children are receiving Rotavac and the other 50% Rotasiil.
Table 2: Vaccine preference, vaccine price per dose, cofinancing, and vaccine introduction year per country
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The incremental delivery cost is based on work by the 
Immunization Costing Action Network. This network 
completed a systematic review of the cost of immunisation 
programmes and developed a unit cost repository.46 The 
repository was searched for incremental costs per dose 
without vaccine cost and returned values for several low­
income and lower­middle­income country studies and 
antigens. We elected to use these values adjusted to 2015 
US$: $1·25 for low­income countries and $1·86 for lower­
middle­income and upper­middle­income countries. This 
data input captured all programmatic costs linked to 
delivering the vaccine, including training costs, staff 
time, and vaccine storage and distribution. As it covers a 
wide range of parameters, we varied this data input in 
probabilistic analysis.
In addition to vaccine price and incremental delivery 
cost, we accounted for a 5% wastage rate for single 
dose vaccines and supplies: 10% for Rotasiil and 
25% for Rotavac to reflect the multidose presentations. 
We accounted for the procurement of safety bags with 
a capacity of 100 doses and a unit cost of $0·80. 
International handling was estimated at 3·5% of the 
vaccine price and international transportation at 6·0%.47 
All inputs used to model cost of the vaccination 
programme are shown in the appendix.
Health service costs
Treatment costs for inpatient and outpatient episodes of 
rotavirus across all 73 Gavi countries were not available. 
We used modelled estimates of direct medical, direct 
non­medical, and indirect costs for both inpatient and 
outpatient episodes. The cost estimation methods are 
described in detail elsewhere (unpublished). In 
summary, we generated country­specific direct medical 
costs using service delivery unit cost estimates from the 
WHO cost­effectiveness and strategic planning tool 
(WHO CHOICE)48 along with commodity costs. For 
inpatients costs, we used country­specific estimates of 
bed day costs at a secondary­level hospital, assuming 
4 days of hospital stay, use of six oral rehydration solution 
packets per day for the duration of hospital stay, and 
two intravenous solutions. For outpatient costs, WHO 
CHOICE data for a primary hospital and six packets of 
oral rehydration solution per day for 2 days were 
assumed. To estimate direct non­medical costs, we first 
derived the share of direct medical to direct non­medical 
costs from the literature. We then used the share of 
direct non­medical cost from the literature and our 
estimate of direct medical cost to calculate the direct 
non­medical cost in each country. Indirect costs were 
calculated by multiplying the average GDP per capita per 
day with the average number of days lost to providing 
care for a patient with diarrhoea. We assumed inpatient 
caretakers lost one productive day and outpatient 
caretakers lost a quarter of a productive day based on an 
unpublished analysis of data from the GEMS study.49 
Only direct medical costs were used in calculating health 
service costs from the government perspective. We 
added direct medical costs, direct non­medical costs, and 
indirect costs in calculating health­service costs from the 
societal perspective. Country­specific health­care costs 
values are available in the appendix.
African region Region of the 
Americas
Eastern 
Mediterranean 
region
European 
region
South-East Asia 
region
Western Pacific 
region
All Gavi countries
Averted rotavirus burden
Cases 64 941 257 2 279 644 14 727 951 3 514 830 66 895 132 6 202 581 158 561 393
Visits 23 883 590 938 830 5 922 875 859 706 15 531 821 1 674 650 48 811 472
Hospitalisations 2 826 609 78 392 392 566 93 906 2 096 962 244 059 5 732 494
Deaths 376 560 3293 57 927 2547 130 824 5417 576 567
DALYs* 9 407 363 89 129 1 488 332 73 308 3 472 376 152 446 14 682 955
Averted health-care costs (US$)
Government perspective* 192 412 959 15 216 757 26 438 853 14 047 862 186 275 477 49 726 662 484 118 569
Societal perspective* 351 173 250 26 076 818 51 733 623 24 427 446 345 072 153 79 549 803 878 033 093
Vaccine programme costs (US$)
With Gavi subsidy* (cost to country only) 1 211 762 128 105 071 230 375 178 351 93 259 104 2 360 479 712 208 622 785 4 354 373 309
Without Gavi subsidy* (cost to country and to Gavi) 2 187 656 303 129 326 733 550 683 257 104 171 153 2 459 017 468 217 671 893 5 648 526 807
Cost per DALY averted (US$)
Government perspective*† 108 
(29–568)
1008 
(71–3389)
234 
(42–463)
1081 
(196–5396)
626 
(242–4529)
1042 
(137–2661)
264 
(202–428)
Societal perspective* 195 1158 335 1088 609 906 325
Cost per DALY averted (government perspective) as a 
proportion of GDP per capita‡
0·09 0·30 0·17 0·50 0·33 0·49 0·16
DALYs=disability-adjusted life-years. GDP=gross domestic product. *Discounted values. †Figures in parentheses show 95% uncertainty intervals (2·5th and 97·5th percentiles of 1000 simulations). ‡GDP per 
capita in current US$ calculated for each region. 
Table 3: Health and economic benefits over a 10-year period (2018–27) for the base-case scenario
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Alternative scenarios and probabilistic analysis
In addition to our base­case scenario covering countries 
with the vaccine they were using in 2018, or a randomly 
allocated vaccine (Rotavac or Rotasiil) for countries that 
were not using rotavirus vaccine at the time of analysis, 
we also explored alternative scenarios looking at the use 
of Rotarix, Rotavac, and Rotasiil in all Gavi count ries. 
We elected to exclude the use of RotaTeq for non­
introducing countries because of the manufacturer’s 
announce ment in 2018 to withdraw from the Gavi mar­
ket.50 Inputs for these alternative scenarios are available 
in the appendix.
We ran probabilistic simulations to account for 
uncertainty in the parameter inputs. We calculated 
the proportion of those simulations with an ICER 
below different possible willingness­to­pay thresholds to 
indicate the probability that the vaccine would be cost­
effective at each threshold. For each country, we gen­
erated 1000 runs of results on the basis of randomly 
selected data inputs using a specified distribution, 
within a range of low and high values for all study 
parameters. The complete set of lower and higher input 
ranges as well as distributions for each input are 
available in the appendix.
Role of the funding source
The funder was not involved in the study design, data 
analysis, interpretation, or reporting of results. The cor­
res ponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication. 
Results
Over the period 2018–27 in Gavi countries, without 
discounting future health benefits, rotavirus vaccination 
has the potential to avert 158·6 million cases of rotavirus 
gastroenteritis, 80·7 million outpatient visits, 7·9 million 
hospitalisations, 576 567 deaths, and 14·7 million DALYs 
(table 3). Of the cases, visits, and hospitalisations averted, 
42% would be in the African region, 41% in the South­
East Asian region, and 9% in the Eastern Mediterranean 
region. Of deaths averted, 65% would be in the African 
region, 23% in the South­East Asian region, and 10% in 
the Eastern Mediterranean region.
In terms of economic benefits, outpatient visits and 
hospitalisations averted represent $484·1 million from 
the government perspective and $878·0 million from 
the societal perspective (table 3). Most of the costs from 
the government perspective are averted in the African 
region, with 40%, 38% in the South­East Asia region, 
and 10% in the Western Pacific region. The total 
vaccination programme cost across all countries is 
estimated to be $4·4 billion, assuming a Gavi subsidy to 
countries, and about $5·6 billion without considering 
Gavi subsidy on vaccine prices. The regional distribution 
of this cost also differs depending on the inclusion 
or exclusion of Gavi support, reflecting regions where 
countries are receiving more support. Without co­
financing, 44% of the global vaccine programme cost 
would be in the South­East Asia region, 39% in the 
African region, and 10% in the Eastern Mediterranean 
region. Accounting for Gavi subsidy, 54% of the cost is 
attributed to countries in the South­East Asia region, 
Figure 1: Map displaying country ICER as a share of GDP per capita from the government perspective
GDP=gross domestic product. ICER=incremental cost-effectiveness ratio. 
0·0 to ≤0·5
>0·5 to ≤1·0
>1·0 to ≤2·0
ICER as a share of national GDP per capita
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28% in the African region, and 9% in the Eastern 
Mediterranean region.
From the societal perspective, incremental cost­effective­
ness ratios expressed in US$ per DALY averted ranged 
from $195 for the African region to $1158 for the region of 
the Americas. Overall from the societal perspective, the 
cost per DALY averted in Gavi countries is $325. From the 
government perspective, the cost per DALY averted ranges 
from $108 for the African region to $1081 for the European 
region. Overall from the government perspective, the cost 
per DALY averted in Gavi countries is $264 (figure 1, 
tables 3 and 4).
From the government perspective, regional ICERs 
represent only a small share of the GDP per capita, ranging 
from 0·09 times GDP per capita in the African region to 
0·50 times GDP per capita in the European region. Across 
Gavi countries, the cost per DALY averted is approximately 
0·16 times GDP per capita.
Results from the probabilistic analysis show that there 
is a very high probability (>90%) that the discounted US$ 
per DALY averted will be less than 0·5 times the national 
GDP per capita in 54 countries and less than 1·0 times 
GDP per capita in 63 countries. Countries where the 
probability of rotavirus vaccination being cost­effective is 
the lowest are in the Americas, Europe, and Western 
Pacific, which is consistent with the results of our 
deterministic analysis (figure 2).
Four countries stand out as having less than 50% 
probability of rotavirus vaccine being cost­effective at 
1·0 times GDP per capita threshold: Armenia, Honduras, 
Moldova, and Ukraine. These four countries are fully 
self­financing countries. The appendix contains the 
results of our alternative scenarios, showing ICERs for 
all different vaccines in each country.
Discussion
Rotavirus vaccination is an impactful and cost­effective 
intervention for a disease that causes around 200 000 deaths 
in children younger than 5 years each year. This analysis 
serves as an important reminder to continue to prioritise 
Number of 
fully 
immunised 
children
Averted cases 
of rotavirus
Averted 
deaths by 
rotavirus
Total health-
care costs 
averted, 
government 
perspective 
(US$)*
Vaccine 
programme 
costs (US$)*
Vaccine 
programme 
costs with Gavi 
subsidy (US$)*
Cost per DALY 
averted, 
government 
perspective (US$)*†
GDP per 
capita (US$)
Afghanistan Rotarix 7 762 176 1 580 540 7305 1 790 959 54 638 902 20 878 029 102 (68–174) 562
Angola Rotarix 9 358 710 2 242 237 30 528 21 333 511 77 669 464 77 669 464 74 (36–119) 3309
Armenia Rotarix 307 794 106 670 9 473 387 2 499 384 2 499 384 4337 (2225–6420) 3615
Azerbaijan Rotavac 1 296 082 256 505 183 1 388 389 10 954 903 10 954 903 1824 (678–3460) 3879
Bangladesh Rotasiil 27 821 356 6 381 993 6038 12 508 907 224 858 236 168 951 095 911 (565–1219) 1359
Benin Rotavac 3 409 188 915 805 6618 2 419 236 23 113 488 13 917 319 69 (37–100) 789
Bhutan Rotavac 130 982 31 051 16 130 410 1 101 703 1 101 703 1993 (851–3758) 2774
Bolivia Rotarix 2 458 502 552 970 820 4 601 265 40 490 928 40 490 928 1599 (868–2513) 3105
Burkina Faso Rotateq 6 938 849 1 741 437 11 105 4 990 861 92 210 089 26 332 567 76 (30–134) 627
Burundi Rotarix 4 369 163 975 496 6008 1 609 641 30 075 387 11 492 083 66 (35–97) 286
Cambodia Rotasiil 3 093 143 693 787 646 1 760 655 25 019 452 17 315 754 855 (480–1222) 1270
Cameroon Rotarix 7 659 052 1 813 529 13 867 7 230 672 61 673 034 39 524 515 93 (55–128) 1375
Central African Republic Rotavac 733 714 269 033 3419 421 169 6 240 284 3 628 809 38 (16–68) 382
Chad Rotasiil 2 812 216 766 128 12 178 1 373 576 21 493 685 12 650 864 39 (20–61) 664
Comoros Rotasiil 228 838 59 906 194 154 074 1 534 044 902 903 150 (77–227) 775
Côte d’Ivoire Rotateq 7 677 006 2 171 684 9889 22 224 658 122 376 764 79 727 547 239 (141–336) 1535
Cuba Rotasiil 1 116 234 508 721 19 6 191 925 8 998 257 8 998 257 1681 (98–4332) 7602
DR Congo Rotasiil 27 297 657 7 268 535 53 013 18 669 915 177 176 708 104 282 116 64 (28–98) 449
Djibouti Rotarix 178 289 40 238 121 127 781 1 441 579 786 340 212 (125–304) 1862
Eritrea Rotarix 1 539 050 261 276 770 421 978 10 611 584 4 155 848 188 (91–303) 583
Ethiopia Rotarix 26 078 179 5 162 506 16 375 7 580 039 187 304 858 72 057 918 152 (85–217) 707
Georgia Rotarix 421 489 192 937 12 738 532 3 395 328 3 395 328 3581 (1805–5246) 3866
Ghana Rotarix 8 085 885 1 775 985 6344 6 160 965 64 090 055 37 213 746 192 (110–265) 1513
Guinea Rotavac 2 600 878 695 933 2897 1 178 462 18 533 035 10 777 108 130 (77–184) 662
Guinea-Bissau Rotarix 584 936 127 634 848 320 995 4 118 150 1 573 583 59 (25–96) 642
Guyana Rotarix 141 621 30 965 46 223 693 2 335 070 2 335 070 1736 (1303–2282) 4529
Haiti Rotarix 1 642 083 380 229 1557 609 246 27 623 504 4 702 378 103 (50–157) 740
Honduras Rotarix 1 920 553 422 385 391 2 083 282 31 797 350 31 797 350 2667 (1978–3549) 2361
(Table 4 continues on next page)
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Number of 
fully 
immunised 
children
Averted cases 
of rotavirus
Averted 
deaths by 
rotavirus
Total health-
care costs 
averted 
government 
perspective 
(US$)*
Vaccine 
programme 
costs (US$)*
Vaccine 
programme 
costs with Gavi 
subsidy (US$)*
Cost per DALY 
averted 
government 
perspective (US$)*†
GDP per 
capita (US$)
(Continued from previous page)
India Rotavac/
Rotasiil
210 355 220 46 083 379 106 007 117 772 708 1 761 981 734 1 761 981 734 588 (428–747) 1710
Indonesia Rotasiil 35 606 711 8 613 368 11 969 41 943 398 320 037 163 320 037 163 866 (463–1306) 3570
Kenya Rotarix 14 630 923 3 225 501 8877 8 233 918 117 831 196 73 903 636 283 (182–383) 1455
Kiribati Rotarix 25 503 5 365 14 23 395 406 410 406 410 1080 (646–1646) 1587
Kyrgyzstan Rotavac 1 219 828 466 414 232 2 902 866 10 203 078 7 256 136 625 (147–1107) 1078
Laos Rotasiil 1 066 947 265 434 1481 2 476 970 9 945 424 9 205 425 177 (99–243) 2339
Lesotho Rotarix 550 446 126 078 594 403 802 4 419 060 2 325 045 133 (79–178) 1040
Liberia Rotarix 1 481 187 352 291 1278 587 456 10 701 360 4 089 089 106 (56–164) 455
Madagascar Rotarix 7 244 209 1 622 511 6370 2 465 080 50 490 355 19 292 831 102 (45–176) 402
Malawi Rotarix 6 138 614 1 487 654 6147 3 486 309 42 520 140 16 247 338 81 (38–121) 300
Mali Rotateq 5 370 633 1 528 415 7623 2 536 699 80 689 518 23 042 622 107 (42–197) 780
Mauritania Rotarix 1 200 458 270 702 1537 870 930 9 887 444 5 457 313 118 (72–166) 1102
Mongolia Rotavac 598 514 234 615 133 976 855 4 904 458 4 904 458 997 (491–1628) 3694
Mozambique Rotarix 10 006 557 2 270 541 9103 4 751 912 70 827 392 27 063 800 97 (49–149) 382
Myanmar Rotavac 8 102 780 2 040 478 4888 4 479 595 68 695 435 49 153 966 351 (351–215) 1196
Nepal Rotavac 4 864 133 1 116 376 816 1 527 722 33 107 970 19 252 409 751 (370–1190) 729
Nicaragua Rotarix 1 092 186 384 373 460 1 507 347 18 081 624 16 747 246 1186 (828–1596) 2151
Niger Rotarix 8 811 793 2 098 720 19 320 3 657 328 63 969 987 24 443 523 43 (21–69) 364
Nigeria Rotavac 35 492 367 10 650 771 91 934 28 485 738 342 230 664 287 705 916 116 (69–169) 2176
North Korea Rotavac 3 272 406 1 214 173 779 2 212 329 22 063 877 12 830 293 467 (231–735) ··
Pakistan Rotarix 37 967 843 8 098 797 23 446 12 209 306 308 853 983 222 737 186 343 (165–567) 1444
Papua New Guinea Rotavac 1 607 485 441 152 1145 1 412 872 14 741 493 14 223 924 432 (298–599) 2500
Moldova Rotarix 319 744 114 889 9 827 754 2 576 006 2 576 006 3433 (1681–5255) 1900
Republic of Congo Rotarix 1 536 206 348 359 1090 4 065 847 12 290 418 12 290 418 292 (97–560) 1528
Rwanda Rotarix 3 585 413 715 749 2539 2 031 404 24 601 057 9 419 779 112 (37–207) 703
São Tomé and Príncipe Rotateq 66 017 15 146 27 169 848 969 103 790 346 729 (453–1378) 1715
Senegal Rotarix 5 356 154 1 078 428 3025 3 505 164 36 891 487 14 096 578 134 (53–217) 953
Sierra Leone Rotarix 2 237 531 494 152 4068 1 096 614 15 995 382 6 111 983 51 (26–78) 505
Solomon Islands Rotasiil 168 506 39 695 35 179 991 1 363 103 1 275 262 1116 (604–1768) 2005
Somalia Rotasiil 2 731 238 791 252 7413 926 056 19 683 313 11 585 139 58 (31–90) 434
South Sudan Rotasiil 1 160 690 362 015 2364 615 357 8 780 072 5 167 745 77 (34–135) 759
Sri Lanka Rotavac 2 868 156 1 315 209 69 4 936 522 23 848 677 23 848 677 3938 (1801–6603) 3835
Sudan Rotarix 12 845 274 2 833 307 14 567 8 823 965 103 124 331 77 184 096 184 (121–245) 2415
Tajikistan Rotarix 2 291 676 515 367 1320 995 629 18 273 646 10 308 538 265 (159–371) 796
Gambia Rotarix 818 934 167 343 533 330 064 5 663 362 2 164 023 137 (41–276) 473
Timor-Leste Rotasiil 391 577 99 103 242 763 884 3 322 673 3 322 673 400 (163–726) 1405
Togo Rotarix 2 416 422 540 639 3061 1 293 933 16 683 379 6 374 873 67 (27–110) 578
Uganda Rotarix 15 696 079 3 497 987 9314 7 773 885 110 814 276 42 343 158 146 (76–212) 580
Ukraine Rotasiil 630 398 692 799 35 3 911 990 10 290 365 10 290 365 2609 (812–4 702) 2072
Tanzania Rotarix 22 592 798 5 235 956 12 673 12 913 994 154 758 157 66 128 551 160 (75–255) 852
Uzbekistan Rotarix 5 772 626 1 169 250 747 2 809 315 45 978 443 45 978 443 1979 (532–4606) 2111
Vietnam Rotavac 14 251 963 4 522 533 1963 42 895 925 161 291 552 161 291 552 1930 (410–5174) 2171
Yemen Rotarix 6 182 800 1 383 818 5075 2 560 785 62 941 149 42 007 560 303 (160–471) 990
Zambia Rotarix 6 573 203 1 560 484 6263 4 279 137 66 609 961 45 525 340 259 (196–316) 1270
Zimbabwe Rotarix 4 669 296 1 044 688 4766 2 768 787 41 811 906 21 871 830 159 (109–210) 1029
DALY=disability-adjusted life-year. GDP=gross domestic product. *Discounted value. †Figures in parentheses show 95% uncertainty intervals (2·5th and 97·5th percentiles of 1000 simulations). 
Table 4: Results by country in the base case scenario (all countries using rotavirus vaccine from 2018 to 2027)
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immunisation in the context of efforts to achieve universal 
health coverage, health equity, and other important 
priorities. Immunisation should continue to be an 
essential component of these efforts, especially for 
countries that face decreasing international financial 
assistance and pressure to achieve additional objectives.
In previous studies, the cost per DALY averted for all 
Gavi­supported countries was reported to be $42.15,16 
Although the ICERs presented here are higher than in 
previous analyses, rotavirus vaccination is likely to be cost­
effective across most Gavi countries, even in countries not 
receiving any support and not accessing lower, Gavi­like 
vaccine prices. Comparison with previous studies is 
not straightforward because of differing methods and 
assumptions; however, results are in line with the various 
trends affecting rotavirus cost­effectiveness, including 
decreases in rotavirus mortality and reduced donor 
support. A comparison of the results presented in this 
Article and the previous analysis15 shows that the largest 
changes in ICERs across Gavi countries are due to 
changes in rotavirus burden estimates and increases in 
the prices countries pay for vaccines as they transition 
from Gavi support.
Like previous analyses, this analysis also shows 
that the health benefits of rotavirus vaccination are 
concentrated in the highest­burden regions.15,16 In 
addition, many of the countries that are most quickly 
transitioning from Gavi support are also the ones with 
a lower burden of disease. Unsurprisingly, rotavirus 
vaccination is less cost­effective in some lower­burden 
regions that pay higher vaccine prices (figures 1, 2). The 
geographies in which rotavirus vaccination is least cost­
effective because of a lower burden and higher vaccine 
costs are those that appear to benefit most from the 
availability of new rotavirus vaccine products with lower 
prices. Such products are appearing on the market as the 
burden is falling and country vaccine costs are rising, 
and as countries shoulder a larger share of their vaccine 
costs, these new lower­cost vaccine products have the 
potential to reduce or to mitigate the effects of declining 
international support. A full product comparison by 
country is beyond the scope of this analysis, but 
additional analyses might illustrate economic benefits 
for lower­cost products in countries with less access to 
Gavi support.
Finally, this analysis and comparison to previous work 
is being undertaken in the context of evolving guid­
ance on cost­effectiveness thresholds. Previous cost­
effectiveness analyses have relied on the guidance from 
the WHO World Health Report, using 3·0 times the GDP 
per capita as a threshold to characterise cost­effective 
interventions, and 1·0 times the GDP per capita for 
highly cost­effective interventions.51 This guidance has 
been updated since 2012, highlighting the need to account 
for additional dimensions when framing cost­effective­
ness results such as affordability, feasibility, and other 
country­specific factors.52 Attempts to refine these norms 
have resulted in more stringent thresholds.53 Although we 
were unable to apply a country­contextualised threshold 
in a global analysis, we did apply more stringent 
willingness­to­pay thresholds. Vaccination has always 
been considered one of the best buys in public health and 
the evolving norms in interpreting cost­effectiveness 
results have not fundamentally changed the outcome of 
our analysis. Rotavirus vaccination still represents good, 
if not excellent, value for money, which is an important 
message for donors such as Gavi and country 
governments.
This analysis includes several limitations worth 
noting. First, we used a transparent and widely used 
static cohort model to estimate only the direct effect 
among vaccinated children. Excluding other indirect 
(herd immunity) effects is likely to underestimate the 
potential impact and value of rotavirus vaccines, so 
results from this Article should be viewed as conservative 
Figure 2: Cost-effectiveness acceptability curves for 72 Gavi countries,* displayed per WHO region
Curves are country-specific and show the probability in the base-case scenario for rotavirus vaccination to be cost-
effective from the government perspective (accounting for Gavi subsidy) at different thresholds. Vertical dotted 
lines represent thresholds of 0·5 times and 1·0 times GDP per capita. GDP=gross domestic product. *North Korea 
was excluded because of the absence of data for GDP per capita. 
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estimates. Second, this is a global analysis. Although we 
explored rotavirus vaccination for 73 countries, several 
input values used for modelling were average values 
at a global or regional level and not country­specific, 
so results should be interpreted cau tiously. A country 
study involving detailed country engagement would 
probably yield improved data inputs leading to more 
accurate results. Third, several data inputs are uncertain. 
In the absence of a reliable measure of treatment­
seeking rates and access to care, we used proportions 
of cases seeking care and DTP1 coverage rate as an 
indicator for access to care and ran a plausibility check 
against the limited country­specific data available in 
the published literature. Further, although we searched 
a comprehensive database to inform cost estimates 
of incremental vaccine programmes, data were not 
available for many countries and we were not able to 
differentiate these costs by vaccine product.46 In 
addition, we projected each country’s Gavi eligibility 
status into the future based on current Gavi status, the 
Gavi transition policy, and projected International 
Monetary Fund growth rates. Although we believe our 
projections are reasonable, economic growth is difficult 
to project and deviations from projections will influence 
Gavi transitions, vaccine prices, and country­specific 
results. Finally, this Article addresses the impact and 
cost­effectiveness of rotavirus vaccination. Although 
value for money is a crucial consideration, affordability 
is also essential and can be examined through a budget 
impact analysis. Although crucial to decision making 
for a country, budget impacts are beyond the scope of 
this analysis. However, our finding that rotavirus 
vaccine is likely to be less cost­effective in countries 
with less international support highlights the 
importance of affordability and the need for such 
analyses.
Overall, rotavirus vaccination offers strong value for 
money across Gavi countries despite important global 
trends contributing to higher cost­effectiveness ratios. 
Countries transitioning away from Gavi support should 
explore newly prequalified vaccines as an option that 
might provide enhanced value for money. Countries 
that have yet to introduce rotavirus vaccination should 
actively consider the potential benefits and cost­
effectiveness of rotavirus vaccination as a step to 
achieving broader health goals.
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